However, the neutralizing antibodies for CCL5 or CXCL10 significantly hampered the migration induced by tumor supernatant (pCCL5 < 0.05; pCXCL10 < 0.01) (Figure 5), and the migration of T lymphocytes was further inhibited by the combined use of anti-CCL5 and anti-CXCL10 neutralizing antibodies (p < 0.001) (Figure 5). The gene discussed is CCL5; the disease is neoplasm.